Title |
Hepatorenal syndrome: the 8th international consensus conference of the Acute Dialysis Quality Initiative (ADQI) Group
|
---|---|
Published in |
Critical Care, February 2012
|
DOI | 10.1186/cc11188 |
Pubmed ID | |
Authors |
Mitra K Nadim, John A Kellum, Andrew Davenport, Florence Wong, Connie Davis, Neesh Pannu, Ashita Tolwani, Rinaldo Bellomo, Yuri S Genyk |
Abstract |
Renal dysfunction is a common complication in patients with end-stage cirrhosis. Since the original publication of the definition and diagnostic criteria for the hepatorenal syndrome (HRS), there have been major advances in our understanding of its pathogenesis. The prognosis of patients with cirrhosis who develop HRS remains poor, with a median survival without liver transplantation of less than six months. However, a number of pharmacological and other therapeutic strategies have now become available which offer the ability to prevent or treat renal dysfunction more effectively in this setting. Accordingly, we sought to review the available evidence, make recommendations and delineate key questions for future studies. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 2 | <1% |
France | 2 | <1% |
Colombia | 1 | <1% |
Brazil | 1 | <1% |
United Kingdom | 1 | <1% |
Germany | 1 | <1% |
Russia | 1 | <1% |
Mexico | 1 | <1% |
Greece | 1 | <1% |
Other | 1 | <1% |
Unknown | 208 | 95% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Postgraduate | 39 | 18% |
Other | 25 | 11% |
Researcher | 23 | 10% |
Professor > Associate Professor | 21 | 10% |
Student > Master | 18 | 8% |
Other | 56 | 25% |
Unknown | 38 | 17% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 158 | 72% |
Agricultural and Biological Sciences | 5 | 2% |
Nursing and Health Professions | 5 | 2% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 1% |
Arts and Humanities | 2 | <1% |
Other | 9 | 4% |
Unknown | 38 | 17% |